MyFiziq's definitive agreement with Active8me further opens up Asian health and wellness market

|

Published 28-APR-2020 09:03 A.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

MyFiziq Limited (ASX: MYQ) has signed definitive agreements with Active8me Pte Ltd which will see the integration of the MyFiziq platform into the Active8me health and wellness platform.

Active8me simplifies healthy, active living in a unique all-in-one mobile platform that incorporates all aspects of healthy living: exercise, nutrition, mindset, and tracking. The app is available via the app store and Google Play.

Active8me is a solution for tackling chronic diseases and an engaging SaaS solution for partners, including insurers, telehealth, mHealth, healthcare providers, corporates, governments, and some of Asia’s largest telecommunications companies.

Founded by two-time Olympian Jeremy Rolleston, Active8me has partners spanning the broader Asia region, which gives MyFiziq the opportunity to tap into millions of potential users of the combined application.

This is a good fit with MyFiziq as it progresses towards globalising its technology which assists individuals, communities and populations to live better healthier lives by working with governments, healthcare providers, and the best health and fitness identities.

The group’s solutions are available worldwide as the data is in the palm of the user’s hands.

MyFiziq’s software as a service solution (SAAS) offering allows flexibility and pricing scale reductions for its partners.

The company partners with highly scaled or scalable new and existing applications and provides them with a deeper insight into the data they wish to retrieve from their users to empower them in their journeys.

Active8me focuses on fitness, nutrition and health

Jeremy Rolleston, has brought together a raft of fitness, nutrition and health experts including dual Olympians Duncan Harvey, Ben St Lawrence and Johanna Lyle, together with Fay Hokulani, Nikki Torres and Jaclyn Reutens, to curate proven programs and customised plans that users can follow to take control of their fitness, health and wellness.

Their range of programs includes Lose Weight, Lean Fit & Toned, Diabetes Prevent, Post Baby, and Running.

The Active8me team has used its industry knowledge and expertise to craft a broad offering that spans multiple lifestyles and personal needs.

It is a one-stop offering with all facets approached on an individual and mass participation needs.

“Active8me is my way of taking all the knowledge I have gained over many years (including as an Olympic athlete and stressed and busy businessman) and, together with a team of other incredible experts, putting it all in an app that gives you a total integrated solution across exercise, nutrition, mindset and holistic health for your real, everyday life. It’s convenient. It’s practical. It’s mobile. It’s a total solution all in one place. It’s great value for money. It’s built with passion by real experts.And it works,” Rolleston says.

The concept of training and setting goals with peers, while at the same time being able to engage privately on whatever level of fitness being commenced is a key advantage as users have varying views on sharing their fitness profiles and training regimes.

Active8me and MyFiziq have agreed to integrate MyFiziq’s body tracking application into the Active8me platform.

The companies are working towards a September quarter 2020 launch with the integrated product along with a comprehensive campaign targeting the current Active8me users and partners.

It is proposed that MyFiziq will be an integral part of the Active8me offering, being a key element for onboarding every user while increasing engagement both during the initial touchpoint of their subscription and then throughout their journey with Active8me as they track their progress.

Governments and insurers have vested interest in a healthy population

Governments, insurers, healthcare providers and consumers are increasingly recognising the rising risks from chronic disease and especially type 2 diabetes disease in Asia.

Identifying those at higher risk of chronic disease and then providing those individuals with comprehensive, integrated and customised plans that they can follow across exercise, nutrition and wellness in a single application provides a convenient expert solution to a problem facing over 40% of the population in Asia.

Additionally, the demand for scalable, digital, at-home health and wellness solutions has never been as significant as now, against a backdrop of Covid-19 quarantine and self-isolation lockdowns.

Active8me and MyFiziq are well positioned to provide helpful solutions to this problem.

The combination of measurement and risk identification, together with actionable and customised programs and plans is a powerful offering.

MyFiziq and Active8me have agreed to the commercial terms of the partnership which will form part of the formal agreements to be concluded in the next 60 days. The initial agreement is for one year, with the option to extend.

The LOI is binding and has no immediate economic impact to MyFiziq.

However, following product launch and anticipated user take up, the LOI and formal agreements that will follow should generate revenue and profit for MyFiziq.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X